NCT05546593 Prevalence of Abnormalities in Ultrasonography of Joint and Tendons in Patients With Gout
| NCT ID | NCT05546593 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Condition | Gout |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2022-08-24 |
| Primary Completion | 2026-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2022-08-24 with a primary completion date of 2026-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Gout is the most frequent inflammatory arthritis in men after 40 years, with a prevalence of 0.9% in France. This disease is characterized by deposits of sodium urate crystals in joints, tendons and soft tissues, which can be detected by ultrasound examination. To date, there was no study assessing inflammatory, structural and deposit lesions due to gout in joints and tendons, since the standardization of ultrasound definitions of gout by the OMERACT (Outcome Measures in Rheumatology) in 2015. The objective of this study is t estimate the prevalence and severity of ultrasound inflammatory lesions (synovitis, tenosynovitis, soft tissues abnormalities), structural lesions (osteophytes, erosions) and abnormalities due to sodium urate deposits (double contour, aggregates, tophi) in patients with gout.
Eligibility Criteria
Inclusion Criteria: Inclusion criteria were adult patients with a diagnosis of gout according to ACR/EULAR 2015 criteria and able to give informed consent. Exclusion criteria were the presence of other chronic inflammatory rheumatic diseases and patients without French social insurance. Exclusion Criteria: \-
Contact & Investigator
Maria-Antonietta D'AGOSTINO, MD, PhD
PRINCIPAL INVESTIGATOR
Rhumatology department, Ambroise Paré hospital - APHP
Frequently Asked Questions
Who can join the NCT05546593 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Gout. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05546593 currently recruiting?
Yes, NCT05546593 is actively recruiting participants. Contact the research team at maria-antonietta.dagostino@aphp.fr for enrollment information.
Where is the NCT05546593 trial being conducted?
This trial is being conducted at Boulogne-Billancourt, France.
Who is sponsoring the NCT05546593 clinical trial?
NCT05546593 is sponsored by Assistance Publique - Hôpitaux de Paris. The principal investigator is Maria-Antonietta D'AGOSTINO, MD, PhD at Rhumatology department, Ambroise Paré hospital - APHP. The trial plans to enroll 200 participants.